Sponsored by Patheon
According to Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical researchers predict a 69% increase in the number of personalized medicines in development over the next five years. Increasingly these advanced, customized therapies demand a cold supply chain. The globalization of clinical trials, the prevailing infrastructure and regulatory environment can significantly impact the design of that supply chain. Even the largest pharmaceutical manufacturers can find the required logistics support to be a maze of confusing and at times, daunting options.